hero-line-left hero-line-top

Leading health systems choose Syapse

Syapse customers treat 10% of cancer patients in the United States.


Syapse is proud to partner with some of the largest health systems in the country to expand access to precision medicine. Our customers manage one million active cancer cases at nearly 300 hospitals in 25 states.

Providence St. Joseph Health

Providence St. Joseph Health launched its Personalized Medicine Program in support of its goal of “whole person care,” which focuses on treating people instead of disease. Providence has displayed a longstanding commitment to delivering high-quality cancer care in the community. Syapse is used by clinicians to provide better access to targeted therapies based on a patient’s clinical and molecular profile.

Catholic Health Initiatives

Catholic Health Initiatives is a nonprofit, faith-based health system formed in 1996. Along with Dignity Health, CHI is a founding member of the Precision Medicine Alliance, forming the nation’s largest collaboration for clinical precision medicine. CHI partnered with Syapse to scale precision medicine across its 103 hospitals, allowing physicians to view integrated clinical and molecular data, learn from real-world evidence, and view recommendations from a molecular tumor board.

Dignity Health

As a founding member of the Precision Medicine Alliance, Dignity Health is committed to delivering personalized cancer care to patients in its community. Across more than 400 care centers, Dignity Health aims to provide the most compassionate and high-quality care to their patients, with special attention to the poor and underserved. To scale the clinical implementation of precision medicine, the Precision Medicine Alliance partnered with Syapse to empower its clinicians through decision support and data sharing collaborations.

Aurora Health Care

Wisconsin-based Aurora Health Care will work with Syapse to implement a precision medicine program, starting in the Vince Lombardi Cancer Clinic at Aurora St. Luke’s Medical Center. The clinic already includes departments such as pathology, research, and genetic counseling, but with the integration of the Syapse Oncology platform, St. Luke’s physicians will be able to pull together relevant information from across the care spectrum to make more efficient and personalized cancer treatment decisions.

Henry Ford Cancer Institute

As a response to the White House’s Cancer Moonshot call to action, Michigan-based Henry Ford Cancer Institute has partnered with Syapse to bring lifesaving precision cancer care to the Midwest. Also a founding member of the Syapse Data Sharing Network, Henry Ford shares robust clinical, molecular, treatment, and outcomes data with other health systems, enabling clinicians to learn from real-world evidence. The partnership with Syapse coincides with the construction of a new $110 million cancer center that aims to bring all stages of care under one roof, supporting patients through every step of their treatment journey.

Banner Health

Banner Health is an Arizona-based system that serves the western United States with 28 hospitals in six states. In many rural areas, Banner’s hospitals are the only inpatient clinics available and thus key providers for communities that may otherwise lack access to specialized care. Through its partnership with Syapse, Banner is empowering its oncology providers and extending the collective knowledge of all Banner’s oncologists across the network.

Hoag Health Network

The Hoag Health Network of California partnered with Syapse to expand the reach and utility of its precision oncology program. Through its integration with Caris, Hoag will bring structured molecular information into clinical contexts for oncology providers. Syapse Oncology will enable physicians to view treatment recommendations and access shared knowledge from across the Syapse Data Sharing Network.  

Stanford Cancer Institute

As a National Cancer Institute-designated Cancer Center, Stanford Cancer Institute is pioneering new approaches to disease treatment and management. Through its partnership with Syapse, SCI is able to harness shared network data and molecular diagnostic information to improve patient care and accelerate clinical research to inform and standardize treatment strategies

University of California, San Francisco

UCSF, one of the leading academic medical centers in the United States, is dedicated to high-quality patient care and biomedical research. UCSF partnered with Syapse in 2014 to scale its precision medicine initiative, making valuable insights available to the clinicians at the point of care. By streamlining the MTB and incorporating decision support into the clinical workflow, oncologists have access to the data they need to make informed treatment decisions.

Seoul National University Hospital

Seoul National University Hospital is one of the country’s top health systems, with access to some of the best clinical trials in the world. SNUH is adopting advanced technology to operationalize their clinical precision medicine efforts. The partnership will enable SNUH to support their clinicians in the delivery of precision medicine to patients across East Asia, and will form the basis for an Asian data sharing network.

Intermountain Healthcare

Since 2014, Syapse Oncology has powered Intermountain Healthcare’s Precision Genomics program, which provides genomics-driven treatment planning and outcomes data to further clinical research and patient care. Through the Precision Genomics initiative, Intermountain has seen a 92% increase in progression-free survival (PFS) with no increase in cost of care per PFS week. Now, Intermountain is scaling its precision medicine program to bring targeted therapies and better outcomes to more members of its community. 

In the news

Amgen taps Syapse to infuse real-world data into its cancer clinical trial designs

5/2/19 - Precision medicine company Syapse has launched a collaboration with its one-time Big Pharma benefactor Amgen, with the goal of mining real-world evidence for insights into cancer drug development. Together, Amgen and Syapse will develop observational research analytics aimed at assessing outcomes in areas of unmet need—starting by identifying existing patients within Syapse’s health network that may be eligible for clinical trials, and then bringing those studies to nearby sites.



Syapse Expands Security Posture with HITRUST Certification

Patient data collected from electronic health records, molecular testing and patient reported outcomes is powering many of the most exciting…